Aug 21 2026 03:00 AM EST

Haemonetics Rallies on Upbeat Outlook and Major Plasma Supply Agreement

Haemonetics Corporation (NYSE: HAE) has seen its shares surge nearly 20% in the past five days, propelled by an upgraded full-year outlook and the announcement of a supply agreement with CSL Plasma, one of the world’s largest plasma collection operators. The developments have reinforced investor confidence in the company’s plasma and hospital technologies businesses, sending the stock to new 52-week highs.

CSL Agreement Strengthens Recurring Revenue Base

The most significant catalyst for Haemonetics’ recent rally was the August 14 announcement of a non-exclusive supply agreement with CSL Plasma. CSL will transition a portion of its U.S. plasma centers to Haemonetics’ NexSys PCS devices with Persona PLUS technology—a system designed to increase plasma yield per donation and support higher collection volumes. While the agreement does not include minimum purchase commitments, investors appeared to interpret the deal as a validation of Haemonetics’ leadership in plasma collection and a new source of recurring revenue.

The news triggered a 16% single-day gain in the shares on August 18, further amplified by positive quarterly results and guidance upgrades earlier in the month.

Quarterly Results and Upgraded Guidance Underpin Optimism

Haemonetics reported first-quarter fiscal 2027 revenue of $339.4 million, up 5.6% year-on-year and above the analyst consensus of $327.9 million to $330.2 million. Adjusted earnings per share rose 4% to $1.14, also ahead of estimates. The company’s operating margin of 16.9% was consistent with the prior year, while free cash flow conversion reached 75% of adjusted net income.

Management responded by raising full-year revenue and adjusted EPS guidance to 5–8% growth, compared with the previous range of 4–7%. Organic revenue growth excluding CSL is expected to reach 7–10%.

Plasma and MedSurg Drive Growth; Analyst Sentiment Turns More Positive

The plasma segment remains Haemonetics’ primary growth engine, supported by the rollout of Persona PLUS, which received FDA clearance in February and is credited with increasing plasma yield per donation. Global plasma collections rose at a high single-digit rate in the U.S. and by double digits in Europe. The MedSurg segment, formerly Hospital, is also contributing, particularly following the expanded FDA labeling for the VASCADE MVP XL vascular closure device and recent product launches.

Analyst sentiment has shifted sharply in recent weeks. Bank of America, Raymond James, Baird, Barrington, and Citi have all raised their price targets, with consensus now near $97 and most ratings at Buy or Outperform. Institutional ownership is high, with recent net insider buying and share buybacks reinforcing conviction in the outlook.

Strategic Portfolio Moves and Industry Tailwinds

Haemonetics has focused its business on high-margin, recurring revenue products, divesting its Whole Blood line in 2025 and acquiring Vivasure Medical, Attune Medical, and OpSens to strengthen its vascular closure and hemostasis technology offerings. The company restructured its reporting lines this quarter to sharpen operational focus, combining Plasma and Blood Center into Apheresis and renaming Hospital as MedSurg.

Broader industry trends—including rising procedure volumes, increased demand for plasma-derived therapies, and the normalization of healthcare utilization—support the company’s recurring consumables model. Regulatory momentum has also been favorable, with several recent FDA approvals and expanded product labeling.

Valuation, Competitive Position, and Principal Risks

Haemonetics now trades at a P/E of 43–44, a premium to historical averages and peer multiples. While analysts highlight robust free cash flow, improved margins, and a strengthened growth profile, Citi and others note that valuation risk has increased, with the stock trading about 21% above certain fair value estimates.

The company maintains a defensible position against competitors such as Terumo BCT, Fresenius Kabi, and Medtronic, due to its installed base, innovation cadence, and high customer switching costs. However, sector headwinds remain, including pricing and reimbursement pressures, customer concentration—44% of revenue comes from the top 10 customers—and ongoing exposure to supply chain disruptions, tariffs, and regulatory changes.

Haemonetics’ recent share-price gains reflect renewed investor confidence in its recurring revenue strategy, strengthened by the CSL supply agreement and robust operating results. Whether the current valuation is sustained will depend on continued execution, the realization of organic growth targets, and the company’s ability to manage competitive and macroeconomic risks.